Nice numbers at 20: what end-of-life evidence does NICE draw on?NICE may be 20 this year, but its policy on end-of-life (EoL) treatments – where NICE can recommend Share XNice numbers at 20: what end-of-life evidence does NICE draw on?https://pharmaphorum.com/views-analysis-market-access/nice-numbers-at-20-what-end-of-life-evidence-does-nice-draw-on/
eyeforpharma Patient Summit Europe roundupeyeforpharma’s Patient Summit Europe brought together leading patient innovators from industry and patient associations for two days of Share Xeyeforpharma Patient Summit Europe rounduphttps://pharmaphorum.com/views-analysis-patients/eyeforpharma-patient-summit-europe-roundup/
Getting MS diagnosis rightMS advocate Trishna Bharadia explains how diagnosis needs to change and why pharma shouldn’t be using the word Share XGetting MS diagnosis righthttps://pharmaphorum.com/views-analysis-patients/getting-ms-diagnosis-right/
Q&A: Sangamo’s Duncan McKay on genomic medicinesWe talk to Duncan McKay, senior vice president and general manager, Europe of Sangamo Therapeutics, about the future Share XQ&A: Sangamo’s Duncan McKay on genomic medicineshttps://pharmaphorum.com/views-analysis-market-access/qa-sangamos-duncan-mckay-on-genomic-medicines/
Why we need a sector-wide emphasis on accessible health informationIn the quest to provide evidence-based health information, the importance of understandable, accessible materials can get lost in Share XWhy we need a sector-wide emphasis on accessible health informationhttps://pharmaphorum.com/views-analysis-patients/why-we-need-a-sector-wide-emphasis-on-accessible-health-information/
Which big pharma firms are best at digital?New research by The Worldcom Public Relations Group has ranked pharmaceutical companies according to their usage of digital Share XWhich big pharma firms are best at digital?https://pharmaphorum.com/views-analysis-digital/which-big-pharma-firms-are-best-at-digital/
Innovative contracting in Europe: a Trojan Horse?By Mary Iyiola & Agnieszka Janska, with additional consultation by Smita Sealey & Barry Farrimond In a recent Share XInnovative contracting in Europe: a Trojan Horse?https://pharmaphorum.com/views-analysis-market-access/innovative-contracting-in-europe-a-trojan-horse-2/
Should you lie to your granny?When it comes to healthcare there are different opinions about patient care east and west, and as market Share XShould you lie to your granny?https://pharmaphorum.com/views-and-analysis/should-you-lie-to-your-granny-healthcare/
Navigating emerging markets – opportunities and challenges for pharmaThe pharmaceutical industry is quickly evolving; to stay relevant and competitive, companies need to stay on top of Share XNavigating emerging markets – opportunities and challenges for pharmahttps://pharmaphorum.com/views-analysis-market-access/navigating-emerging-markets-opportunities-and-challenges-for-pharma/
